Logan, UT, January 17, 2020 – ELITechGroup Inc., recognized worldwide as slide staining and cytocentrifuge technologic pioneers and innovators, with nearly 30 patents, over the 35-year lifespan of Aerospray staining technology, announces the launch of the Aerospray Cytology Slide Stainer Cytocentrifuge. The ELITechGroup’s Aerospray Cytology Slide Stainer/Cytocentrifuge automates the preparation and staining of liquid based cytology specimens to facilitate the examination of an array of cell differentiations utilizing Papanicolaou staining techniques. The advantages of the Aerospray Cytology Slide Stainer/Cytocentrifuge is that the device performs two functions of sample preparation through cytocentrifugation and sample staining. The system maximizes cell recovery to the slide through the use of its Cytopro® Rotor, eliminates cross-contamination with an application of fresh stain for each slide, and provides programmable regressive and progressive staining capabilities that can be stored in memory to meet the needs and preferences of any end user. The instrument standardizes staining across multiple labs, provides consistently high-quality control, is low maintenance, reduces the labor/cost per slide, enables laboratory compliance, and is the perfect back-up for high automation laboratories for specialty staining and during maintenance. “ELITechGroup’s portfolio of Aerospray slide stainers and cytocentrifuges has enabled the company to develop a worldwide reputation for performance and reliability. Our new Aerospray Cytology Stainer/Cytocentrifuge proves our commitment to ongoing innovation by expanding into new laboratories where we can offer superior staining results,” says Bryce McEuen, Vice President, Biomedical Systems. ELITechGroup will be showcasing the Aerospray Cytology Slide Stainer/Cytocentrifuge at key industry events throughout the year of 2020. Learn more at AerosprayStaining.com.
About ELITechGroup
ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents for clinical systems, microbiology, molecular diagnostics, hematology, cytology, and sweat test systems. Their mission is to improve patient care by empowering laboratories to do more in less time, with accuracy, to enable rapid and accurate course of treatment for patients.
Read more
Shimadzu introduces new HIC-ESP ion chromatograph
, /in Product News /by 3wmediaShimadzu, a leader in analytical instrumentation, has introduced the new HIC-ESP (Ion Chromatograph) featuring a built-in electrodialytic suppressor. This anion suppressor minimizes band spreading and achieves high sensitivity and reliable performance for the quantitative determination of anions.
The suppressor is rugged, providing stable functionality over long periods of operation. The system’s small footprint requires minimal bench space. HIC-ESP covers a wide range of applications in environmental testing, pharma, chemistry and food science.
The HIC-ESP modular inert flow path system integrates a system controller, degasser, pump, CDD detector with temperature-controlled flow cell, autosampler, slim-line oven and the anion suppressor. The system combines a number of special features providing reliable analytical results: Excellent solvent delivery performance, low carryover, fast injection speed (as low as 10 sec), high sample injection precision and repeatability, precise oven temperature regulation and more.
In addition, the ion chromatography system integrates seamlessly with Shimadzu’s LabSolutions platform. This allows users to easily manage parameter setting for IC analysis, batch analyses, autoshutdown, data processing and report creation. Data integrity is assured with the addition of LabSolutions DB and LabSolutions CS.
For more information, visit: www.shimadzu.eu/ liquid-chromatography/nexera/hicesp
Read more
Oxford Immunotec releases T-SPOT Discovery SARS-CoV-2 kit for research into measuring T cell immune response to SARS-CoV-2
, /in Corona News, Product News /by 3wmediaOxford Immunotec Global has released the T-SPOT Discovery SARS-CoV-2 test kit. The kit is for research use only and could make a significant contribution towards development of a new tool to manage the COVID-19 pandemic.
T-SPOT Discovery SARS-CoV-2 builds on Oxford Immunotec’s experience with TB diagnosis and the assessment of immune response to CMV in transplant patients, to apply the Company’s established, proprietary T-SPOT technology to the fight against COVID-19.
While serology is able to detect antibodies to SARS-CoV-2 in the blood of some individuals after infection, little is known about how this confers immunity to COVID-19. T-SPOT technology goes further than simple serology by interrogating the immune system’s T cell response and will enable research into the measurement of the strength of that response to SARS-CoV-2. The strength of this response may be linked to protection from reinfection.
Commenting on the technology, Phill Keefe, Senior Vice President Product Design, Development and Delivery at Oxford Immunotec, said: “Not everyone with COVID-19 infection has detectable antibodies in serology tests, and this may be a bigger problem in the majority who experience only mild or no symptoms. Also, it is not yet clear whether the presence of anti-bodies confers immunity. T cell responses develop before antibody generation and can independently provide protection, so studying T cells could give us new insights into immunity to COVID-19.”
T-SPOT technology is approved in over 60 countries for clinical use to detect TB infection. With over 20 million clinical tests since release, T-SPOT technology:
– Reduces the influence of factors which might affect results, such as other treatments
– Standardises cell numbers in the test to normalise for cell number variations between samples
T-SPOT technology can also be automated using the T-Cell Select reagent kit. Automation solutions are available for low, medium and high throughput settings.
For more information, visit: go.oxfordimmunotec. com/t-spot_discovery_SARS_CoV-2
Read more
Ansh labs launches two new immunoassays for SARS-COV2
, /in Corona News, Product News /by 3wmediaAnsh labs has launched two new immunoassays, SARS-CoV2 IgG and IgM ELISAs, to assist in the fight against the Covid-19 pandemic.
Ansh Labs is releasing these two kits for sale in the United States under the provisions outlined in Section D of Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. At the time of going to press, these tests were under review by the FDA for an Emergency Use Authorization.
IgM antibody is the first to be produced in response to viral proteins (antigens) and will be primarily detectable during the early onset of the disease. IgG antibodies are long-lasting and can persist in the bloodstream for many years after infection. This test has the advantage of detecting not only individuals with active infection (IgM), but also those who were previously exposed to the virus and may have subsequently developed immunity (IgG).
Testing for SARS-CoV2 antibodies can help in epidemiological surveillance about the spread of the virus and possible herd immunity. Ansh Labs’ SARS-CoV2 ELISAs are highly accurate with IgG ELISA offering 96% specificity and IgM ELISA offering 99% specificity.
For more information, visit: www.covid-diagnostics.com
Read more
ELITechGroup’s Staining Technology Expands with Aerospray® Cytology Slide Stainer/Cytocentrifuge
, /in Product News /by 3wmediaLogan, UT, January 17, 2020 – ELITechGroup Inc., recognized worldwide as slide staining and cytocentrifuge technologic pioneers and innovators, with nearly 30 patents, over the 35-year lifespan of Aerospray staining technology, announces the launch of the Aerospray Cytology Slide Stainer Cytocentrifuge. The ELITechGroup’s Aerospray Cytology Slide Stainer/Cytocentrifuge automates the preparation and staining of liquid based cytology specimens to facilitate the examination of an array of cell differentiations utilizing Papanicolaou staining techniques. The advantages of the Aerospray Cytology Slide Stainer/Cytocentrifuge is that the device performs two functions of sample preparation through cytocentrifugation and sample staining. The system maximizes cell recovery to the slide through the use of its Cytopro® Rotor, eliminates cross-contamination with an application of fresh stain for each slide, and provides programmable regressive and progressive staining capabilities that can be stored in memory to meet the needs and preferences of any end user. The instrument standardizes staining across multiple labs, provides consistently high-quality control, is low maintenance, reduces the labor/cost per slide, enables laboratory compliance, and is the perfect back-up for high automation laboratories for specialty staining and during maintenance. “ELITechGroup’s portfolio of Aerospray slide stainers and cytocentrifuges has enabled the company to develop a worldwide reputation for performance and reliability. Our new Aerospray Cytology Stainer/Cytocentrifuge proves our commitment to ongoing innovation by expanding into new laboratories where we can offer superior staining results,” says Bryce McEuen, Vice President, Biomedical Systems. ELITechGroup will be showcasing the Aerospray Cytology Slide Stainer/Cytocentrifuge at key industry events throughout the year of 2020. Learn more at AerosprayStaining.com.
About ELITechGroup
ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents for clinical systems, microbiology, molecular diagnostics, hematology, cytology, and sweat test systems. Their mission is to improve patient care by empowering laboratories to do more in less time, with accuracy, to enable rapid and accurate course of treatment for patients.
Read more
NovaTec Immundiagnostica’s assays aid diagnosis of SARS-COV-2
, /in Corona News, Product News /by 3wmediaNovaTec provides reliable direct pathogen and antibody detection assays to aid in the diagnosis of SARS-CoV-2. These tests are CE-IVD marked. The development of the assays has been spearheaded by affiliate companies Gold Standard Diagnostics, NovaTec Immundiagnostica, and VIROTECH Diagnostics.
The NovaLisa SARS-CoV-2 (COVID-19) ELISA serological assays feature separate detection of IgG, IgA, and IgM antibodies. These three assays use the nucleocapsid protein (N protein) as antigen for the detection of antibodies to SARS-CoV-2, as it plays an important role in viral pathogenesis, replication and RNA packaging. NovaLisa assays can be automated on several open ELISA systems to provide quick results.
The GSD NovaPrime SARS-CoV-2 is a onestep reverse transcription multiplex Real-Time PCR for the direct detection of SARS-CoV-2. The assay simultaneously detects two target sequences inside the N gene. The multiplex PCR enables a streamlined workflow in one reaction and provides results in approximately 2 hours. An extraction/inhibition control and a positive control are included in the kits. The PCR assay demonstrates excellent performance and no cross-reactivity with common human coronavirus strains.
Read more
EURORealTime MTB test provides direct detection of TB pathogens
, /in Product News /by 3wmediaTuberculosis is one of the most prevalent infectious diseases worldwide, with 10 million new cases and an estimated 1.8 million fatalities per year according to the WHO. It is caused by pathogens of the Mycobacterium tuberculosis complex (MTBC). EUROIMMUN’s EURORealTime MTB test provides reliable direct detection of all bacteria of the MTBC in sputum, bronchoalveolar fluid and bronchial secretion by means of real-time polymerase chain reaction (real-time PCR).
The detection is based on three MTBC-specific target regions, encompassing a large number of genetic variants. The target sequences are amplified in a single multiplex PCR using highly specific primers and detected by real-time analytics. Numerous integrated controls ensure high result integrity.
The evaluation and interpretation of results is fully automated using the EURORealTime Analysis software and is thus highly standardised. The software also guides the user through the individual work steps, ensuring a simple and error-free test procedure. The entire process from sample to report release is IVD validated and CE registered.
The direct detection of tuberculosis pathogens complements other diagnostic methods such as microscopy and detection by culturing, which takes as long as 6 to 8 weeks. The PCRbased analysis thus supports early treatment and prevention of transmission.
For more information, visit: www.euroimmun.com
Read more
Beckman Coulter’s SARS-CoV-2 IgG antibody test now available in markets accepting CE Mark
, /in Product News /by 3wmediaBeckman Coulter’s Access SARS-CoV-2 IgG assay is now available in markets accepting the CE Mark, the company said in statement 15 June. It has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the United States and has begun shipping to customers globally. Beckman Coulter has more than 16,000 immunoassay analysers worldwide and has increased manufacturing to deliver more than 30 million tests a month.
Many of Beckman Coulter’s analysers can deliver up to 400 routine tests an hour. The Access SARS-CoV-2 IgG test can also be run on Beckman Coulter’s Access 2 analyser, a compact table-top analyser enabling high-quality serology testing to be carried out in small hospitals and clinics.
The Access SARS-CoV-2 IgG Assay is a qualitative immunoassay that detects IgG antibodies directed to the receptor-binding domain of the spike protein of the novel coronavirus that is driving the ongoing global pandemic. It is believed that these antibodies have the potential to be neutralizing antibodies and may play a role in lasting immunity. The test has a confirmed 99.8% specificity and 100% sensitivity at 18 days post PCR confirmed positive test. The assay uses immobilized virus antigens on magnetic particles to capture IgG antibodies from patient serum or plasma samples and reveals them using labelled anti-IgG antibodies.
Commenting on the assay, Shamiram R. Feinglass, M.D., MPH, Chief Medical Officer, Beckman Coulter, said: “An IgG antibody assay such as the test Beckman Coulter has developed can provide valuable information regarding community levels of immunity that will inform public health decision making and rollout of a vaccine when one does become available. The very high sensitivity and specificity of this assay provides a high positive predictive value, even when the overall incidence of disease is low. Additionally, since our assay can be run on multiple different types of analysers, it can be adapted to a variety of healthcare settings to best meet the needs of each community.”
Read more
COVID-19: Antibody & Molecular Testing Solutions by NovaTec Immundiagnostica GmbH
, /in Corona News, Product News /by 3wmediaNovaTec is excited to collaborate in the fight against COVID-19 providing reliable direct pathogen and antibody detection assays to aid in the diagnosis of SARS-CoV-2. These tests are CE-IVD marked and immediately available. The development of the assays has been spearheaded by affiliate companies Gold Standard Diagnostics Inc., NovaTec Immundiagnostica GmbH, and VIROTECH Diagnostics GmbH.
The NovaLisa® SARS-CoV-2 (COVID-19) ELISA serological assays feature separate detection of IgG, IgA, and IgM antibodies. These three assays use the nucleocapsid protein (N protein) as antigen for the detection of antibodies to SARS-CoV-2, as it plays an important role in viral pathogenesis, replication and RNA packaging. NovaLisa® assays can be automated on several open ELISA systems providing quick results.
The GSD NovaPrime® SARS-CoV-2 (COVID-19) is a one-step reverse transcription multiplex Real-Time PCR for the direct detection of SARS-CoV-2. The assay simultaneously detects two target sequences inside the N gene. The multiplex PCR allows a streamlined workflow in one reaction and provides results in approximately 2 hours. An extraction/inhibition control and a positive control are included in the kits. The PCR assay demonstrates excellent performance and no cross-reactivity with common human coronavirus strains.
Read more
Retinol-Binding Protein (RBP), and other urinary low molecular weight protein assays, as markers of renal tubular function
, /in Product News /by 3wmediaTRIMERO Diagnostics offers IVD CE urinary assays of low molecular weight proteins, by nephelometry or turbidimetry, for the assessment of renal tubular function:
These assays, specifically designed for their use on urine samples, are available for the nephelometers and the most popular clinical chemistry analyzers present in the market.
Other TRIMERO’s available nephelometric and turbidimetric assays include:
Serum Amyloid A (SAA), IgD Immunoglobulins, Soluble Transferrin Receptor (sTfR), Hemopexin, Complement C1q, Complement C5, Factor B (C3 Proactivator), C1 (Esterase) Inhibitor.
Read more
ChIP kits for high throughput antibody validation
, /in Product News /by 3wmediaPorvair Sciences report how its Chromatrap ChIP kits provide an outstanding solution for antibodies suppliers looking to validate the performance of the antibodies they produce for chromatin immunoprecipitation (ChIP) assay kits.
With its revolutionary bead-free system, Chromatrap offers a faster, easier and more sensitive method to validate antibodies in a high throughput format. This enables antibody suppliers to easily and efficiently expand their product portfolio to target epigenetics and drug development applications.
Successful ChIP assays heavily rely on the highest quality antibodies. In-house validation of antibodies for use in ChIP is considered to be a lengthy, expensive, time consuming and challenging process. In addition, antibodies are rigorously assessed for enrichment of positive and negative gene targets, signal-to-noise ratio, chromatin-to-antibody ratio, reproducibility and lot-to-lot variations.
Dr Lindsay Parkes, a senior research scientist at Porvair Sciences commented: “We have developed our bead-free Chromatrap technology to enable maximum capture of antibody. This is achieved by correctly orientated capture proteins throughout the inert filter-based ChIP technology. Most bead-based systems have capture proteins scattered in random orientation which doesn’t allow full access of antibodies to binding pockets of proteins, thus giving an overall reduced capture efficiency. This is important for high sensitivity especially for detection of binding of low abundant targets.”
Chromatrap ChIP kits deliver fast workflow, enabling you to process up to 96 ChIP assays simultaneously in one day allowing multiple sample, antibody and gene targets to be tested in parallel on a single plate. Requiring less manual handling and fewer pipetting steps than other ChIP kits, Chromatrap ChIP kits are very easy to use, making them perfect for even inexperienced users. Using these kits, a complete ChIP protocol doesn’t require overnight incubation or blocking steps and can be completed in under five hours. Chromatrap ChIP-kits are suitable for use over a wide chromatin enrichment range (500ng – 50µg).
For further information on Chromatrap® ChIP kits for antibody validation, visit: https://www.chromatrap.com/high-throughput-chip-kits/
Read more